drugset
drugset / Trial / NCT06429033

Purified Exosome Product (PEP) Injected Into the Hypodermis

NCT06429033 ↗

Phase 1 Completed 8 enrolled Clinical Testing of Beverly Hills
NaSequentialOpen-labelOther

Summary

This clinical trial aims to characterize the safety, tolerability, and histological profile of PEP (Purified Exosome Product) when injected into the hypodermis of healthy adults. The main questions this study aims to answer are: Is PEP safe and tolerable when injected into the hypodermis of healthy adults? Subjects will serve as their own control and researchers will compare PEP to Control to see if PEP is safe.

Timeline

Start
2025-04-14
Primary completion
2025-12-17
Completion
2025-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Purified Exosome Product Other / unclassified 75 mg Subcutaneous
Subject Purified Exosome Product Other / unclassified 150 mg Subcutaneous

Indications

No indication recorded.